Home » Stocks » ATHX

Athersys, Inc. (ATHX)

Stock Price: $1.63 USD 0.01 (0.62%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
After-hours: $1.64 +0.01 (0.61%) Jun 11, 7:49 PM
Market Cap 362.00M
Revenue (ttm) 1.44M
Net Income (ttm) -89.59M
Shares Out 208.19M
EPS (ttm) -0.45
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $1.63
Previous Close $1.62
Change ($) 0.01
Change (%) 0.62%
Day's Open 1.63
Day's Range 1.61 - 1.64
Day's Volume 691,907
52-Week Range 1.40 - 3.30

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys reports First Quarter 2021 financial results and will provide a corporate update today at 4:30 PM EDT.

1 month ago - Business Wire

CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Ivor Macleod, CFO of Athersys Inc. is scheduled to speak at the Bank of America Securities 2021 Virtual Health Care Conference on May 12th.

1 month ago - Business Wire

Athersys, Inc. (ATHX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 month ago - Zacks Investment Research

CLEVELAND--(BUSINESS WIRE)---- $ATHX #earnings--Athersys, Inc. will host its first quarter 2021 financial results call on Thursday, May 6, 2021 at 4:30 PM EDT.

1 month ago - Business Wire

CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference on April 14th and the event will be webcast.

2 months ago - Business Wire

The biotech's partner completed enrollment in a key clinical study.

2 months ago - The Motley Fool

CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--Athersys partner in Japan, HEALIOS KK, completes enrollment in the ONE-BRIDGE study evaluating MulitiStem cell therapy for the treatment of ARDS.

2 months ago - Business Wire

CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--Athersys continues to develop large-scale manufacturing processes and advance MultiStem cell therapy clinical trials for stroke, ARDS, and trauma.

2 months ago - Business Wire

CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys will host the year-end 2020 financial results call on March 25th.

3 months ago - Business Wire

CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys and Healios commit to work in good faith to finalize negotiations important to successful commercialization in Japan.

3 months ago - Business Wire

CLEVELAND, Ohio--(BUSINESS WIRE)---- $ATHX #Athersys--Gil Van Bokkelen to Step Down as Chairman and CEO of Athersys

3 months ago - Business Wire

Athersys: Risky Financial Position, But Promising Upside By FYE 2023

4 months ago - Seeking Alpha

CLEVELAND, Ohio--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys will host a virtual investor day event on February 16th to cover development progress and commercial manufacturing plans.

4 months ago - Business Wire

Athersys (ATHX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

5 months ago - Zacks Investment Research

The biotech announced the enrollment of the first patient in a key clinical study.

5 months ago - The Motley Fool

CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--UTHealth and Athersys announce patient enrollment in an innovative clinical study of MultiStem® cell therapy for the treatment of traumatic injuries

5 months ago - Business Wire

CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys announces three appointments to its board of directors, deepening board expertise to prepare for future growth and commercialization.

6 months ago - Business Wire

Athersys has taken its time in developing an interesting pipeline which has potential to offer outsized rewards. Athersys' US timeline for its ischemic stroke indication keeps challenging investors' pat...

7 months ago - Seeking Alpha

Athersys, Inc.'s (ATHX) CEO Gil Van Bokkelen on Q3 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

Athersys, Inc. (ATHX) CEO Gil Van Bokkelen On Q3 2020 Results - Quick Version Earnings Call Transcript

7 months ago - Seeking Alpha

CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys announces Q3 earnings and initiation of MultiStem® Phase 2 clinical trial in patients with trauma related inflammation and complications

7 months ago - Business Wire

CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys, Inc. (Nasdaq: ATHX) will release its third quarter 2020 financial results on Monday, November 9, 2020.

8 months ago - Business Wire

Investors need to pay close attention to Athersys (ATHX) stock based on the movements in the options market lately.

8 months ago - Zacks Investment Research

The FDA bestows a Regenerative Medicine Advanced Therapy status on Athersys' (ATHX) MultiStem cell therapy candidate for treating acute respiratory distress syndrome.

8 months ago - Zacks Investment Research

CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--MultiStem is the only cell therapy program for acute respiratory distress syndrome (ARDS) that has both Fast Track and RMAT designation from the FDA.

8 months ago - Business Wire

Athersys: Still An Abundance Of Opportunity

9 months ago - Seeking Alpha

Athersys, Inc. (ATHX) CEO Gil Van Bokkelen on Q2 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys has made progress during Q2 in key clinical programs and infrastructure to support its planned transition to becoming a commercial company.

10 months ago - Business Wire

CLEVELAND--(BUSINESS WIRE)---- $ATHX #Athersys--Athersys, Inc. (Nasdaq: ATHX) will release its second quarter 2020 financial results on Monday, August 10, 2020.

10 months ago - Business Wire

The stem cell stock jumped after a major Wall Street firm initiated coverage, but there's a catch.

11 months ago - The Motley Fool

The stem cell stock recovered from a lousy April as the company fed investors updates for its COVID-19 programs.

1 year ago - The Motley Fool

Below is a list of six companies with promising Covid-19 treatments in various stages of development, and the reasons why I have invested in them.

Other stocks mentioned: CMRX, CTSO, CYDY, MESO
1 year ago - Seeking Alpha

Athersys: Fare Well

1 year ago - Seeking Alpha

Athersys Inc.s' (ATHX) CEO Gil Van Bokkelen on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

The stem cell stock has delivered a 100% gain since the beginning of the year. Can it hold?

1 year ago - The Motley Fool

Promising results from a very small study caused shares of stem cell stocks to soar, but investors shouldn't get too carried away just yet.

Other stocks mentioned: MESO, PSTI
1 year ago - The Motley Fool

Athersys: Abundance Of Opportunity

1 year ago - Seeking Alpha

The stem cell developer decided to wisely take advantage of a soaring share price to raise funds.

1 year ago - The Motley Fool

With the coronavirus outbreak gaining steam worldwide, pharma/biotech companies are evaluating every possible therapy to combat the spread.

Other stocks mentioned: GILD, JNJ, MESO, PFE, PSTI, REGN
1 year ago - Zacks Investment Research

As the COVID-19 pandemic continues to ravage the globe, having claimed over 115,000 lives, health care companies have are pursuing diagnostics tests, potential vaccines and therapies.

Other stocks mentioned: BCRX, BIOC, CANF
1 year ago - Benzinga

Shares of Athersys Inc. ATHX, -2.02% shot up 26.5% in premarket trading Monday, after the company said it has received Food and Drug Administration authorization to start a phase 2/3 trial to assess saf...

1 year ago - Market Watch

Athersys Inc.: MultiStem Cell Therapy Is The Most Advanced And Tested Treatment For ARDS, And Thus COVID-19

1 year ago - Seeking Alpha

Athersys - Now In Play For COVID-19 - FDA Fast Tracked Therapy For ARDS

1 year ago - Seeking Alpha

Athersys' (ATHX) CEO Gil Van Bokkelen on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Athersys And The Law Of Large Numbers

1 year ago - Seeking Alpha

Athersys & The Law Of Large Numbers

1 year ago - Seeking Alpha

Highly experienced pharmaceutical industry executive joins leadership team as Company begins planning for potential approval and commercialization of MultiStem® Highly experienced pharmaceutical industr...

1 year ago - GlobeNewsWire

One-year results support positive 28-day findings and suggest further benefits for ARDS patients One-year results support positive 28-day findings and suggest further benefits for ARDS patients

1 year ago - GlobeNewsWire

Designation will expedite review for HLCM051 (MultiStem® Cell Therapy) for ARDS program in Japan Designation will expedite review for HLCM051 (MultiStem® Cell Therapy) for ARDS program in Japan

1 year ago - GlobeNewsWire

Athersys, Inc. (ATHX) CEO Gil Van Bokkelen on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

About ATHX

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as ... [Read more...]

Industry
Biotechnology
Founded
1995
CEO
Gil Van Bokkelen
Employees
97
Stock Exchange
NASDAQ
Ticker Symbol
ATHX
Full Company Profile

Financial Performance

In 2020, Athersys's revenue was $1.44 million, a decrease of -74.44% compared to the previous year's $5.63 million. Losses were -$78.77 million, 76.7% more than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Athersys stock is "Strong Buy." The 12-month stock price forecast is 5.25, which is an increase of 222.09% from the latest price.

Price Target
$5.25
(222.09% upside)
Analyst Consensus: Strong Buy